Sanofi (SNY) : Zacks Investment Research ranks Sanofi (SNY) as 4, which is a Sell recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.
Sanofi (SNY) : 2 Wall Street analysts covering Sanofi (SNY) believe that the average level the stock could reach for the short term is $54.5. The maximum price target given is $56 and the minimum target for short term is around $53, hence the standard deviation is calculated at $2.12.
For the current week, the company shares have a recommendation consensus of Buy. Sanofi (NYSE:SNY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.03 and $39.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.32. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.29, notching a gain of 1.15% for the day. The total traded volume was 898,154 . The stock had closed at $39.83 on the previous day.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.